AMENDMENTS TO THE CLAIMS

Listing of Claims:

1. (Original) Racemic tolterodine free base in crystalline form.

2. (Previously Presented) Racemic tolterodine free base in crystalline form according to claim 1 containing less than about 0.2% of dimeric impurity.

3 (Currently Amended) Tolterodine according to claim 2, wherein the dimeric impurity comprises one or both of the following impurities:

Dimer 1:



Dimer 2:



4. (Original) A process of preparing racemic tolterodine free base in crystalline form, which comprises deprotection of protected intermediate of formula (II)



(II)

wherein a solvent is present in the reaction mass obtained further to the deprotection and is selected so that a substantially mobile reaction mass is achieved at temperatures in the range of 70 to 100°C.

5. (Original) A process according to claim 4, wherein said deprotection employs pyridine hydrochloride.

6. (Original) A process according to claim 5, wherein said deprotection is carried out under an inert atmosphere at a temperature in the range of 200 to 220°C.

7. (Original) A process according to claim 6, wherein further to said deprotection said reaction mass is cooled to a temperature in the range of 110 to 130°C and said solvent is added thereto.

8. (Previously Presented) A process according to claim 4, wherein said solvent is dimethylformamide.

9. (Previously Presented) A process according to claim 5, wherein the resulting crude hydrochloride salt of racemic tolterodine is basified and the resulting racemic tolterodine free base extracted and precipitated to provide crystalline racemic tolterodine free base.

10. (Previously Presented) A process according to claim 9, which further comprises a purification step to obtain racemic tolterodine free base in crystalline form containing less than about 0.2% of dimeric impurity.

11. (Previously Presented) A process according to claim 10, which further comprises resolving the thus obtained racemic tolterodine free base to obtain (+)tolterodine tartrate containing less than about 0.1% of dimeric impurity.

12. (Currently Amended) A process according to claim 11, wherein said dimeric impurity comprises one or both of the following impurities:

Dimer 1:



Dimer 2:



13-14. (Canceled)

15. (Original) A process of preparing racemic tolterodine free base in crystalline form, which process comprises deprotection of a benzyl protected intermediate of formula (III)



(III)

where R_a represents unsubstituted benzyl, or a substituted benzyl protecting group.

16. (Previously Presented) A process according to claim 15, which further comprises resolving the thus obtained racemic tolterodine free base to obtain (+)tolterodine tartrate containing less than about 0.1% of dimeric impurity.

17. (Previously Presented) A process according to claim 16, wherein R_a represents unsubstituted benzyl.

18. (Previously Presented) A process according to claim 15, wherein an intermediate compound of formula (III) is prepared by reaction of diisopropylamine with an intermediate compound of formula (IV)



(IV)

where X represents a leaving group.

19. (Original) A process according to claim 18, wherein X represents arylsulphonyloxy.

20. (Original) A process according to claim 19, wherein X represents tosylate.

21. (Previously Presented) A process according to claim 18, wherein an intermediate compound of formula (IV) is prepared from an intermediate compound of formula (V)



(V)

22. (Previously Presented) A process according to claim 21, wherein a compound of formula (V) is prepared by protection of an intermediate compound of formula (VI)



(VI)

by introduction of group R_a.

23. (Original) A process according to claim 22, wherein a compound of formula (VI) is prepared from 6-methyl-4-phenyl-chroman-2-one.

24-25. (Canceled)

26. (Previously Presented) An intermediate compound of formula (V) or (VI):



(V) (VI)

where R_a represents unsubstituted benzyl, or a substituted benzyl protecting group.

27. (Original) An intermediate of formula (V) according to claim 26, wherein R_a represents unsubstituted benzyl.

28. (Canceled)

29. (Previously Presented) A pharmaceutical composition comprising tolterodine according to claim 1, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

30-33. (Canceled)